NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm CEO to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 14, 2016
CEO Dr. Lieberman will give a corporate overview and discuss the company’s flagship product candidates designed to treat moderate to severe Parkinson’s disease. ”> Read More
NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson’s Disease
First Clinical Efficacy Study Investigating ND0612H Subcutaneously Delivered Liquid Levodopa/Carbidopa for the Treatment of Advanced Parkinson’s Disease.”> Read More
NeuroDerm Added to the Nasdaq Biotechnology Index
The Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).> Read More